Cure.’s Post

Navigating the FDA approval process can be daunting, but it doesn't have to be. Our latest blog post, "Demystifying the US Biopharma FDA Approval Process," breaks down the key steps, programs, and considerations to ensure a smooth journey for innovative therapies to reach patients. From understanding standard and priority review to exploring options like Fast Track Designation and Orphan Drug status, this easy-to-understand guide aims to explain the key terms and concepts in drug approval journey. Ready to demystify the FDA process? Read the full article here: https://shorturl.at/pDPY6 #drugdevelopment #fda #fdaapproval #clinicaltrials #strategy #regulatoryaffairs #healthcare #clinicalresearch #lifesciences

Pharma has recognized that there is a problem with diversity in clinical trials but has so far struggled to successfully achieve real change. This article covers how the US FDA has updated its guidance documents to demand that trial sponsors must make diversity part of their planning. Read more: https://ow.ly/LbEO30sFuQ3

By expediting the FDA drug review process, priority review vouchers help first and best-in-class treatments reach people who need them most. Our latest white paper shows how the PRV program is a proven incentive driving innovation that benefits patients. Learn more here: https://lnkd.in/e4A9nwkj #RareDiseases #DrugDevelopment

Register today! With state drug price transparency laws and requirements constantly changing and evolving, it’s important for pharmaceutical manufacturers to be in the know. Learn about the latest happenings how to be proactive from the session hosted by Marbls!

2023 was a landmark year for the FDA's Center for Drug Evaluation and Research (CDER) division, as they approved a significant number of novel drugs. These advancements promise new horizons in patient care and treatment options across various conditions. An impressive lineup of novel drugs received approval, emphasizing the industry's focus on cutting-edge research and development. These approvals span a wide range of therapeutic areas, underscoring the FDA's commitment to addressing unmet medical needs and enhancing quality of life. The momentum in drug approvals sets a promising tone for continued innovation and patient-centric healthcare solutions. #Regulatory #HealthcareInnovation #FDAApprovals2023 #PatientCare #MedicalBreakthroughs #regulatorysubmissions Advancing Health Through Innovation: New Drug Therapy Approvals 2023: https://lnkd.in/gEy4dhBU

Visit, read my Landing page of #newslatter "Pharma Artificial Intelligence Digest" Dive into Artificial Intelligence-driven pharmacy advancements with us. Get exclusive updates on drug development, from early breakthroughs to FDA approvals. Empowering pharmacy professionals through knowledge sharing is our mission. https://lnkd.in/drS-z4M6

Why choose us to support your clinical development strategy? Our team reflects the structure of an FDA, EMA, or Notified Bodies Reviewer’s Team. We offer integrated guidance to help you successfully bring your product to market. Learn more about working with us or discuss your development strategy with our expert delegates onsite at Swiss Biotech Day: https://lnkd.in/eiwGQjT3 #clinicaldevelopment #biotech #swissbiotechday

Delays caused by regulatory hurdles are preventing patients from accessing drugs that could save their lives. It is critical that biopharma and diagnostic providers have the necessary tools to navigate the regulatory requirements and accelerate approvals. Covering everything from LDT updates, IVDR, reimbursement and more, this summit is your chance to stay ahead of the curve and listen to the thought leaders who are sharply navigating confusing regulatory requirements; download the brochure below to see this comprehensive agenda, where you can learn from the leaders, collaborate, and improve your regulatory strategies: https://ter.li/3ahhpw This is free to attend (see t&c) for academics and drug developers. For service providers in the space - you can save over $200 if you register before this Friday (17th)! Here is a sneak peak at some of our top industry leaders: Jai Pandey, PhD, Vihanga Pahalawatta, Lori Roadcap, Andrea Renninger, Claudia Dollins, Mary J. Savage, Deb Rasmussen, Ralph Riley, Dun Liang, Andrew L'Huillier, Sid Mathur, Qing Li, MD. PhD, Kaska (Katarzyna) Kowanetz, PhD, RAC, Brian Baker and more Download the brochure here: https://ter.li/3ahhpw

Thoughts on this? >> FDA publishes long-awaited guidance on clinical trial diversity >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #productmarketing #healthcare